| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,229.8 |
-15.95 (-1.28%) |
Mid Cap | 33,700 | 50.3 | 11.44 | 24.5 | 2.7 | |
| Lupin | Pharmaceuticals& Drugs | 2,491.8 |
22.35 (0.91%) |
Mid Cap | 27,958 | 116.6 | 18.82 | 21.4 | 5.1 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,154.4 |
20.55 (1.81%) |
Mid Cap | 27,148 | 50.5 | 16.54 | 22.9 | 4.4 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,295.1 |
-10.45 (-0.45%) |
Mid Cap | 13,322 | 48.3 | 9.67 | 47.6 | 6.2 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,551.2 |
-1.65 (-0.11%) |
Mid Cap | 10,933 | 42 | 15.17 | 37 | 3.9 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,546.6 |
16.1 (0.64%) |
Mid Cap | 10,421 | 49.3 | 19.97 | 51.6 | 6.4 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,667.5 |
69.1 (1.23%) |
Mid Cap | 8,813 | 182.8 | 23.18 | 31 | 4.8 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,877.6 |
37.55 (2.04%) |
Mid Cap | 7,289 | 44.6 | 16.38 | 42.1 | 6 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,554.9 |
-4.95 (-0.32%) |
Mid Cap | 6,813 | 16.5 | 12.82 | 94.5 | 15.9 | |
| Abbott India | Pharmaceuticals& Drugs | 27,632.4 |
112.35 (0.41%) |
Mid Cap | 6,409 | 730.4 | 22.1 | 37.8 | 12.3 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,453 |
38.55 (1.13%) |
Mid Cap | 5,453 | 84.5 | 19.33 | 40.9 | 9.5 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,485.7 |
22.1 (0.9%) |
Mid Cap | 3,822 | 61.2 | 25.36 | 40.7 | 18.4 | |
| Biocon | Pharmaceuticals& Drugs | 434.7 |
-2.65 (-0.61%) |
Mid Cap | 2,243 | 0.2 | 8.04 | 1,904.2 | 2.6 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 751.5 |
1.35 (0.18%) |
Mid Cap | 2,089 | 11.9 | 30.95 | 63.1 | 13.4 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: